Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegylated orthogonal IL-2 STK-009

A polyethylene glycol (PEG)-conjugated mutein form of the cytokine interleukin-2 (IL-2), with potential and specific activity on enhancing proliferation, survival and anti-tumor activity of engineered orthoIL-2Rb-expressing CAR T cells. Upon subcutaneous administration, pegylated orthogonal (ortho) IL-2 STK-009 specifically targets and binds to mutated orthoIL-2Rbeta (hoRbeta; hoRb) that is specifically expressed on certain engineered CAR T cells. This induces selective proliferation, survival, and cytotoxic function of orthoIL-2Rbeta-expressing CAR T cells, which enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation. STK-009 does not bind to the wild type (WT) IL-2b receptor and does not activate IL-2-mediated signaling in bystander T and NK cells, thereby limiting systemic toxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:orthogonal IL-2 ligand STK-009
orthogonal IL-2 STK-009
orthoIL-2 STK-009
pegylated IL-2 mutein STK-009
Code name:STK 009
STK-009
STK009
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search